{
    "nctId": "NCT01471847",
    "briefTitle": "A Phase Ib/II Study of BEZ235 and Trastuzumab in Patients With HER2-positive Breast Cancer Who Failed Prior to Trastuzumab",
    "officialTitle": "A Phase Ib/Randomized Phase II Study of BEZ235 and Trastuzumab Versus Lapatinib and Capecitabine in Patients With HER2-positive Locally Advanced or Metastatic Breast Cancer Who Failed Prior to Trastuzumab",
    "overallStatus": "COMPLETED",
    "conditions": "Locally Advance Breast Cancer (LABC), Metastatic Breast Cancer (MBC)",
    "studyType": "INTERVENTIONAL",
    "phase": "PHASE1",
    "allocation": "RANDOMIZED",
    "primaryPurpose": "TREATMENT",
    "enrollmentCount": 5,
    "primaryOutcomeMeasure": "Incidence of Dose Limiting Toxicities (DLT) in the first cycle - phase lb",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patient is a female \u2265 18 years of age\n* Patient has a histologically and/or cytologically confirmed diagnosis of HER2-positive invasive breast cancer with inoperable locally advanced or metastatic disease\n* Patients with controlled or asymptomatic CNS metastases are eligible\n* Patient has adequate bone marrow and organ functions, and has recovery from all clinically significant toxicities related to prior anti-neoplastic therapies\n* Absolute neutrophil count (ANC) \u2265 1.5 x 109/L\n* Platelets \u2265 100 x 109/L\n* Hemoglobin (Hgb) \u2265 9.0 g/dL\n* INR \u2264 2\n* Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) \u2264 3 x ULN (or \u2264 5.0 x ULN if liver metastases are present)\n* Total serum bilirubin \u2264 1.5 x ULN (in patients with known Gilbert Syndrome, a total bilirubin \u2264 3.0 x ULN, with direct bilirubin \u2264 1.5 x ULN)\n* Serum creatinine \u2264 1.5 x ULN\n* Fasting plasma glucose (FPG) \u2264 140mg/dL \\[7.8 mmol/L\\]\n* HbA1c \u2264 8%\n* Patient has received prior trastuzumab (alone or in combination) but NO more than 3 prior cytotoxic chemotherapy lines\n* Prior endocrine and radiotherapy allowed\n* Patient has ECOG performance status of 0-2 (Phase Ib) or 0-1 (Phase II)\n\nAdditional inclusion criteria for phase II:\n\n* Available tumor tissue (archival or fresh) for biomarker analysis; known PI3K activation status\n* At least one measurable lesion as per RECIST 1.1\n* Patient has received prior treatment with a taxane\n* Patient has \"trastuzumab-resistance disease\" defined as:\n* Recurrence while on trastuzumab (or T-DM1) or within 12 months since the last infusion in the adjuvant setting\n* Progression while on or within 4 weeks since the last infusion of trastuzumab (or T-DM1) in the locally advanced or metastatic setting\n\nExclusion Criteria:\n\n* Previous treatment with PI3K and/or mTOR inhibitors\n* Symptomatic/uncontrolled Central Nervous System (CNS) metastases\n* Concurrent malignancy or malignancy in the last 3 years prior to enrollment\n* Wide field radiotherapy \u2264 28 days or limited field radiation for palliation \u2264 14 days prior to starting study drug\n* Active cardiac disease (e.g. LVEF less than institutional lower limit of normal, QTcF \\> 480 msec, unstable angina pectoris, ventricular, supraventricular or nodal arrhythmias)\n* Inadequately controlled hypertension\n* Impairment of gastrointestinal (GI) function or GI disease that may significantly alter the absorption of BEZ235\n* Treatment at start of study treatment with drugs with a known risk to induce Torsades de Pointes, moderate and strong inhibitors or inducers of isoenzyme CYP3A4, warfarin and coumadin analogues, LHRH agonists\n* Intolerance or contraindications to trastuzumab treatment\n* Pregnant or nursing (lactating) woman\n\nAdditional exclusion criteria for phase II:\n\n* Prior treatment with capecitabine and lapatinib\n* Intolerance or contraindications to capecitabine and lapatinib\n* Previous treatment with HER-2 targeted agents other than trastuzumab or T-DM1\n* Peripheral neuropathy \u2265 Grade 2",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}